University of Virginia (UVA) School of Medicine researchers have created an atlas of atherosclerosis that reveals, at the level of individual cells, critical processes responsible for forming the harmful plaque buildup that causes heart attacks, strokes, and coronary artery disease.
Doctors and scientists have been eager to better understand the complex factors that influence the formation and stability of the plaques, and UVA’s new work offers insights that will facilitate the development of new ways to treat atherosclerosis, battle coronary artery disease (CAD), and help prevent plaque formation.
“To begin to develop effective treatments targeting specific disease processes in the vessel wall, we need to characterize gene expression programs at single-cell resolution,” said researcher Clint L. Miller, PhD, of the University of Virginia School of Medicine’s Center for Public Health Genomics, as well as its departments of biochemistry and molecular genetics and public health sciences. “By establishing this map, we can inform strategies to reprogram dysregulated cell states in order to prevent or reverse the disease or identify biomarkers to assess a patient’s risk of having clinical events.”
The team published its study, “Integrative single-cell meta-analysis reveals disease-relevant vascular cell states and markers in human atherosclerosis,” in Cell Reports.
“CAD progression involves complex interactions and phenotypic plasticity among vascular and immune cell lineages. Single-cell RNA-seq (scRNA-seq) studies have highlighted lineage-specific transcriptomic signatures, but human cell phenotypes remain controversial. Here, we perform an integrated meta-analysis of 22 scRNA-seq libraries to generate a comprehensive map of human atherosclerosis with 118,578 cells. Besides characterizing granular cell-type diversity and communication, we leverage this atlas to provide insights into smooth muscle cell (SMC) modulation,” the investigators wrote.
“We integrate genome-wide association study data and uncover a critical role for modulated SMC phenotypes in CAD, myocardial infarction, and coronary calcification. Finally, we identify fibromyocyte/fibrochondrogenic SMC markers (LTBP1 and CRTAC1) as proxies of atherosclerosis progression and validate these through omics and spatial imaging analyses. Altogether, we create a unified atlas of human atherosclerosis informing cell state-specific mechanistic and translational studies of cardiovascular diseases.”
Understanding atherosclerosis
The formation of atherosclerotic plaques involves multiple types of cells, including immune cells, smooth muscle cells, and endothelial cells that line the arteries. Many of these cells transition into other types of cells during plaque formation, making it a huge challenge for scientists to determine the composition and origin of the plaque itself.
Miller and his collaborators, led by graduate student Jose Verdezoto Mosquera, have built a comprehensive single-cell map of human atherosclerosis encompassing almost 120,000 cells from atherosclerotic coronary and carotid arteries. In addition to charting broad cell lineages, the researchers leveraged this resource to dissect more granular and rare cell subtypes within atherosclerotic plaques.
The study also reveals new insights into the changes smooth muscle cells go through during disease progression, some of which contribute to the calcification of the coronary arteries. This led to the finding that two genes, LTBP1 and CRTAC1, can serve as measures for the progression of atherosclerosis.
“Beyond characterizing cell diversity, integrating this newly built atherosclerosis single-cell reference with large-scale human genetic data was critical to start identifying disease-causing cell types and subtypes,” Mosquera said. “For example, we identified the contribution of smooth muscle cell subtypes, such as fibroblast-like and lipid-rich smooth muscle cells, as well as the genes associated with these phenotypes.”
The UVA researchers say their new atlas represents a critical step toward developing better, more targeted interventions to battle atherosclerosis and CAD, as well as identifying candidate biomarkers to prevent heart attacks and strokes and improve patient outcomes.
“We plan to extend this single-cell atlas with future iterations to include additional datasets from defined disease stages and patients from diverse backgrounds,” Miller said. “By integrating the corpus of single-cell data generated in the scientific community, we can mitigate sampling bias and establish more robust candidate disease mechanisms and potential interventions.”